Also known as gastric inhibitory polypeptide and GIP.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.
First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.
First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.
